Cybin Inc., a clinical-stage neuropsychiatry company, filed a prospectus supplement on December 30, 2025, for an at-the-market equity offering of up to US$100 million (approximately C$136.9 million) in common shares. The offering is being conducted through Cantor Fitzgerald Canada Corporation as Canadian agent and Cantor Fitzgerald & Co. as U.S. agent, with the agents receiving a 3% commission on gross sales. Expected net proceeds to the corporation will not exceed US$97 million (approximately C$132.8 million). Sales will be made at prevailing market prices through at-the-market distributions on Cboe Canada and Nasdaq.

Aird & Berlis LLP and Dorsey & Whitney LLP serve as legal counsel to Cybin for Canadian and U.S. matters respectively, while Bennett Jones LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represent the agents. The corporation intends to use net proceeds for growth opportunities and working capital initiatives. Concurrently with the offering, Cybin's shares are transitioning from NYSE American to Nasdaq Global Market, with trading under the new ticker symbol "HELP" commencing January 5, 2026, replacing the previous "CYBN" symbol.